FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / Effect of 5′-adenosine monophosphate-activated protein...
Journal of veterinary internal medicine2023; 38(1); 102-110; doi: 10.1111/jvim.16970

Effect of 5′-adenosine monophosphate-activated protein kinase agonists on insulin and glucose dynamics in experimentally induced insulin dysregulation in horses.

Abstract: 5'-adenosine monophosphate-activated protein kinase (AMPK) agonists, particularly resveratrol (RES), have not been extensively evaluated for their effect on insulin dysregulation (ID) in horses. Objective: Evaluate the effects of treatment with RES (10 mg/kg PO q12h), metformin (MET; 30 mg/kg PO q12h), and aspirin (ASP; 20 mg/kg PO q24h) on experimentally induced ID. Methods: Thirty-three healthy, adult, light-breed horses. Methods: Unblinded, placebo-controlled, experimental trial evaluating effects of AMPK agonists (RES, MET, and ASP) on experimentally induced ID. Horses were randomly assigned to a treatment group (RES, MET/ASP, RES/ASP, RES/MET/ASP, or placebo [CON]) after induction of ID with dexamethasone (0.08 mg/kg PO q24h for 7 days). Frequently sampled insulin-modified IV glucose tolerance tests (FSIGTT) and oral sugar tests (OST) were performed at baseline, 7 days after ID, and ID plus 7 days of treatment. Minimal model and OST variables were compared between (1-way ANOVA) and within (1-way ANOVA for repeated measures) groups over time to determine effects of treatment on ID. Results: Administration of dexamethasone for 14 days resulted in significantly altered insulin and glucose dynamics (SI, DI, basal [glucose], and [insulin]) and produced clinical signs of laminitis in 5 out of 33 (15%) of horses included in the study. Combination therapy with RES, MET, and ASP did not significantly improve insulin and glucose dynamics in horses with experimentally induced ID. Conclusions: Metabolic testing before glucocorticoid administration should be considered in horses with clinical signs of metabolic syndrome.
© 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2023-12-13 PubMed ID: 38088223PubMed Central: PMC10800176DOI: 10.1111/jvim.16970Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Randomized Controlled Trial
  • Veterinary
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the effects of various protein kinase agonists on insulin and glucose dynamics in horses with experimentally induced insulin dysregulation. The researchers found that combination therapy of these agonists did not significantly improve these dynamics in the studied horses.

Introduction and Objective

  • The research focuses on the impact of 5′-adenosine monophosphate-activated protein kinase (AMPK) agonists on insulin dysregulation (ID) in horses. ID is associated with the potential development of laminitis, a severe foot condition in horses.
  • The study particularly evaluates the treatment effects of resveratrol (RES), metformin (MET), and aspirin (ASP).

Methods

  • Treatment groups were randomly assigned to the healthy adult light-breed horses after ID induction with dexamethasone. The groups included RES, MET/ASP, RES/ASP, RES/MET/ASP, and placebo.
  • Both frequently sampled insulin-modified IV glucose tolerance tests (FSIGTT) and oral sugar tests (OST) were utilized before and after ID induction, as well as after the treatment period of 7 days.
  • The study compares the minimal model and OST variables over time within and between the groups to judge the impact of the treatments on insulin dysregulation.

Results

  • The induction of ID with dexamethasone over 14 days significantly altered insulin and glucose dynamics and produced laminitis symptoms in 15% of the horses.
  • The combination treatment of RES, MET, and ASP did not notably improve the insulin and glucose dynamics.

Conclusions

  • Essentially, the study suggests the potential risk of ID and laminitis due to glucocorticoid administration in horses exhibiting metabolic syndrome symptomatology.
  • Therefore, metabolic testing is recommended prior to glucocorticoid administration in horses presenting metabolic syndrome clinical signs.

Cite This Article

APA
Pinnell EF, Hostnik LD, Watts MR, Timko KJ, Thriffiley AA, Stover MR, Koenig LE, Gorman OM, Toribio RE, Burns TA. (2023). Effect of 5′-adenosine monophosphate-activated protein kinase agonists on insulin and glucose dynamics in experimentally induced insulin dysregulation in horses. J Vet Intern Med, 38(1), 102-110. https://doi.org/10.1111/jvim.16970

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 38
Issue: 1
Pages: 102-110

Researcher Affiliations

Pinnell, Erin F
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
  • Department of Veterinary Clinical Sciences, Washington State University College of Veterinary Medicine, Pullman, Washington, USA.
Hostnik, Laura D
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
Watts, Mauria R
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
Timko, Kathryn J
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
Thriffiley, Allison A
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
Stover, Mercedes R
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
Koenig, Lauren E
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
Gorman, Olivia M
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
Toribio, Ramiro E
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
Burns, Teresa A
  • Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.

MeSH Terms

  • Horses
  • Animals
  • Glucose / metabolism
  • Insulin / metabolism
  • Blood Glucose
  • Glucose Tolerance Test / veterinary
  • AMP-Activated Protein Kinases
  • Dexamethasone / pharmacology
  • Dexamethasone / therapeutic use
  • Adenosine Monophosphate
  • Horse Diseases / diagnosis

Grant Funding

  • Grayson Jockey Club Research Foundation

Conflict of Interest Statement

Authors declare no conflict of interest.

References

This article includes 40 references
  1. Durham AE, Frank N, McGowan CM. ECEIM consensus statement on equine metabolic syndrome. J Vet Intern Med 2019;33:335‐349.
    pmc: PMC6430910pubmed: 30724412
  2. Frank N, Tadros EM. Insulin dysregulation. Equine Vet J 2014;46:103‐112.
    pubmed: 24033478
  3. Asplin KE, Sillence MN, Pollitt CC, McGowan CM. Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies. Vet J 2007;174:530‐535.
    pubmed: 17719811
  4. de Laat MA, McGowan CM, Sillence MN. Equine laminitis: induced by 48 h hyperinsulinaemia in Standardbred horses. Equine Vet J 2010;42:129‐135.
    pubmed: 20156248
  5. Hustace JL, Firshman AM, Mata JE. Pharmacokinetics and bioavailability of metformin in horses. Am J Vet Res 2009;70:665‐668.
    pubmed: 19405907
  6. Tinworth KD, Edwards S, Noble GK. Pharmacokinetics of metformin after enteral administration in insulin‐resistant ponies. Am J Vet Res 2010;71:1201‐1206.
    pubmed: 20919907
  7. Rendle DI, Rutledge F, Hughes KJ, Heller J, Durham AE. Effects of metformin hydrochloride on blood glucose and insulin responses to oral dextrose in horses. Equine Vet J 2013;45:751‐754.
    pubmed: 23600690
  8. Durham AE, Rendle DI, Newton JE. The effect of metformin on measurements of insulin sensitivity and beta cell response in 18 horses and ponies with insulin resistance. Equine Vet J 2008;40:493‐500.
    pubmed: 18482898
  9. Tinworth KD, Boston RC, Harris PA, Sillence MN, Raidal SL, Noble GK. The effect of oral metformin on insulin sensitivity in insulin‐resistant ponies. Vet J 2012;191:79‐84.
    pubmed: 21349749
  10. Ford RJ, Fullerton MD, Pinkosky SL. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem J 2015;468:125‐132.
    pmc: PMC5233440pubmed: 25742316
  11. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013;123:2764‐2772.
    pmc: PMC3696539pubmed: 23863634
  12. Cork GK, Thompson J, Slawson C. Real talk: the inter‐play between the mTOR, AMPK, and hexosamine biosynthetic pathways in cell signaling. Front Endocrinol (Lausanne) 2018;9:522.
    pmc: PMC6136272pubmed: 30237786
  13. Burns TA, Watts MR, Weber PS, McCutcheon LJ, Geor RJ, Belknap JK. Effect of dietary nonstructural carbohydrate content on activation of 5′‐adenosine monophosphate‐activated protein kinase in liver, skeletal muscle, and digital laminae of lean and obese ponies. J Vet Intern Med 2014;28:1280‐1288.
    pmc: PMC4857936pubmed: 24750267
  14. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non‐insulin‐dependent diabetes mellitus. Drugs 1995;49:721‐749.
    pubmed: 7601013
  15. Mannucci E, Ognibene A, Cremasco F. Effect of metformin on glucagon‐like peptide 1 (GLP‐1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489‐494.
    pubmed: 11289473
  16. Xiao C, Giacca A, Lewis GF. The effect of high‐dose sodium salicylate on chronically elevated plasma nonesterified fatty acid‐induced insulin resistance and beta‐cell dysfunction in overweight and obese nondiabetic men. Am J Physiol Endocrinol Metab 2009;297:E1205‐E1211.
    pubmed: 19755670
  17. Zhang L, Li J, Young LH, Caplan MJ. AMP‐activated protein kinase regulates the assembly of epithelial tight junctions. Proc Natl Acad Sci U S A 2006;103:17272‐17277.
    pmc: PMC1859922pubmed: 17088526
  18. Hou CY, Tain YL, Yu HR, Huang LT. The effects of resveratrol in the treatment of metabolic syndrome. Int J Mol Sci 2019;20(3):535‐550.
    pmc: PMC6387422pubmed: 30695995
  19. Alayev A, Berger SM, Holz MK. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation. Ann N Y Acad Sci 2015;1348:116‐123.
    pubmed: 26200935
  20. Lane HE, Burns TA, Hegedus OC. Lamellar events related to insulin‐like growth factor‐1 receptor signalling in two models relevant to endocrinopathic laminitis. Equine Vet J 2017;49:643‐654.
    pubmed: 28078757
  21. Timko KJ, Hostnik LD, Watts MR. Diagnostic evaluation of insulin and glucose dynamics in light‐breed horses receiving dexamethasone. Can Vet J 2022;63:617‐626.
    pmc: PMC9112365pubmed: 35656529
  22. Brennan KM, Urschel KL. Recovery of insulin sensitivity in mature horses after a 3 week course of dexamethasone therapy. Equine Vet J 2014;46:718‐721.
    pubmed: 24533602
  23. Tiley HA, Geor RJ, McCutcheon LJ. Effects of dexamethasone on glucose dynamics and insulin sensitivity in healthy horses. Am J Vet Res 2007;68:753‐759.
    pubmed: 17605611
  24. Lindase S, Nostell K, Brojer J. A modified oral sugar test for evaluation of insulin and glucose dynamics in horses. Acta Vet Scand 2016;58:64.
    pmc: PMC5073908pubmed: 27766982
  25. Hackett ES, McCue PM. Evaluation of a veterinary glucometer for use in horses. J Vet Intern Med 2010;24:617‐621.
    pubmed: 20337908
  26. Cunneen A, Wood KA, Mathison K. Comparison of a continuous indwelling glucometer with a point‐of‐care device in healthy adult horses. Vet Rec 2020;187:e21.
    pubmed: 32179578
  27. Toth F, Frank N, Elliott SB. Optimisation of the frequently sampled intravenous glucose tolerance test to reduce urinary glucose spilling in horses. Equine Vet J 2009;41:844‐851.
    pubmed: 20383980
  28. Rings LM, Swink JM, Dunbar LK, Burns TA, Toribio RE. Enteroinsular axis response to carbohydrates and fasting in healthy newborn foals. J Vet Intern Med 2019;33:2752‐2764.
    pmc: PMC6872622pubmed: 31664736
  29. Johnson PJ, Slight SH, Ganjam VK, Kreeger JM. Glucocorticoids and laminitis in the horse. Vet Clin North Am Equine Pract 2002;18:219‐236.
    pubmed: 15635906
  30. Bamford NJ, Potter SJ, Harris PA, Bailey SR. Breed differences in insulin sensitivity and insulinemic responses to oral glucose in horses and ponies of moderate body condition score. Domest Anim Endocrinol 2014;47:101‐107.
    pubmed: 24308928
  31. Norton EM, Schultz NE, Rendahl AK. Heritability of metabolic traits associated with equine metabolic syndrome in welsh ponies and Morgan horses. Equine Vet J 2019;51:475‐480.
    pubmed: 30472742
  32. de Laat MA, Reiche DB, Sillence MN, McGree JM. Incidence and risk factors for recurrence of endocrinopathic laminitis in horses. J Vet Intern Med 2019;33:1473‐1482.
    pmc: PMC6524073pubmed: 30972832
  33. de Laat MA, Sillence MN, Reiche DB. Phenotypic, hormonal, and clinical characteristics of equine endocrinopathic laminitis. J Vet Intern Med 2019;33:1456‐1463.
    pmc: PMC6524085pubmed: 30697823
  34. Most J, Timmers S, Warnke I. Combined epigallocatechin‐3‐gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. Am J Clin Nutr 2016;104:215‐227.
    pubmed: 27194304
  35. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012;32:537‐541.
    pubmed: 22901562
  36. Zare Javid A, Hormoznejad R, Yousefimanesh HA. The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Phytother Res 2017;31:108‐114.
    pubmed: 27807887
  37. Gong L, Guo S, Zou Z. Resveratrol ameliorates metabolic disorders and insulin resistance in high‐fat diet‐fed mice. Life Sci 2020;242:117212.
    pubmed: 31884092
  38. Huang DD, Shi G, Jiang Y, Yao C, Zhu C. A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. Biomed Pharmacother 2020;125:109767.
    pubmed: 32058210
  39. Manfredi JM, Stapley ED, Nadeau JA, Nash D. Investigation of the effects of a dietary supplement on insulin and adipokine concentrations in equine metabolic syndrome/insulin dysregulation. J Equine Vet 2020;88:102930.
    pubmed: 32303322
  40. Treiber KH, Kronfield S, Hess TM. Use of proxies and quintiles obtained from minimal model analysis for determination of insulin sensitivity and pancreatic beta‐cell responsiveness in horses. Am J Vet Res 2005;66(12):2114‐21121.
    pubmed: 16379656
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.